Showcase Furniture Adds Porter King Panel Bed to its Latest Bedroom Collection

Showcase Furniture, a prominent provider of residential furnishings, recently announced the addition of a significant ...
MedPage Today

Complement Inhibitor Slowed Kidney Decline in IgA Nephropathy

Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...
Verywell Health

What Happens to Your Body When You Eat Foods That Support Healthy Cells

Learn what happens in your body when you eat foods that support cellular health, including how nutrients protect cells, reduce inflammation, and support energy.
TechRepublic

Project Management Information Systems Explained: Functions, Tools & Examples

Explore how project management information systems guide each project phase, the tools that support them, and real-world use across industries. Project management information systems extend far beyond ...
Seeking Alpha

Omeros Announces First Commercial Sales of YARTEMLEA®

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
Seeking Alpha

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...
Investing

Omeros stock soars after FDA approves first treatment for TA-TMA

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock surged 61.6% Wednesday after the FDA approved YARTEMLEA, the first and only treatment for hematopoietic stem cell transplant-associated ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...